Compare CAC & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAC | ARTL |
|---|---|---|
| Founded | 1875 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 801.9M | 3.5M |
| IPO Year | 1997 | N/A |
| Metric | CAC | ARTL |
|---|---|---|
| Price | $49.98 | $1.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $45.50 | $30.00 |
| AVG Volume (30 Days) | ★ 105.0K | 35.2K |
| Earning Date | 01-27-2026 | 03-02-2026 |
| Dividend Yield | ★ 3.40% | N/A |
| EPS Growth | ★ 6.08 | N/A |
| EPS | ★ 3.84 | N/A |
| Revenue | ★ $233,489,000.00 | N/A |
| Revenue This Year | $19.32 | N/A |
| Revenue Next Year | $5.90 | N/A |
| P/E Ratio | $12.88 | ★ N/A |
| Revenue Growth | ★ 31.62 | N/A |
| 52 Week Low | $34.53 | $1.15 |
| 52 Week High | $51.57 | $28.60 |
| Indicator | CAC | ARTL |
|---|---|---|
| Relative Strength Index (RSI) | 60.23 | 30.68 |
| Support Level | $48.74 | $1.35 |
| Resistance Level | $50.60 | $1.52 |
| Average True Range (ATR) | 1.45 | 0.14 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 66.04 | 4.29 |
Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.